General Investment Approach
Where does TechWald Holding invest?
TechWald Holding (TWH) has no strict geographical constraints. However, we tend to prefer companies located near our operational bases to provide stronger and more consistent support. For this reason, we primarily invest in Europe and Israel, while maintaining strong connections with the U.S. market.
What is the minimum or maximum ticket size?
We do not have a fixed minimum or maximum ticket size. Typically, our first investment ranges between €1–5 million, but we remain highly flexible depending on the company’s specific needs.
How does a holding company differ from a fund?
While both are investment vehicles, a holding company like TWH invests its own capital with no predefined exit timeline, often playing an active operational role in its portfolio companies. In contrast, a fund pools external capital to make time-limited investments defined by a specific strategy, geography, and investment size, with the goal of exiting within a set period.
About the Holding
What is TechWald’s investment thesis?
We support high-growth companies that are committed to driving innovation in – medical devices, equipment, digital technologies, and related services – that deliver value to patients, physicians, and healthcare systems, while generating sound and ethical returns for shareholders. We prefer companies at a First in Human stage.
What sectors within MedTech do you focus on?
Our core focus is on cardiology (including structural heart, electrophysiology, and cardiovascular technologies). We also invest in neurology, neurovascular, metabolic diseases (e.g., diabetes, obesity), and orthopedics. That said, TWH remains open and curious about new frontiers within medical devices in healthcare.
What is your typical investment stage?
We typically invest after a company has reached First-in-Human (FIH) stage. However, we are flexible and evaluate each opportunity on its merits.
What differentiates you from others in the industry?
Our team consists of experienced professionals with deep expertise in the MedTech space. This enables us to scout high-potential opportunities and support them throughout their development with rigor, reliability, and strategic guidance.
For Portfolio Companies / Startups
What do you look for in a MedTech startup?
A promising and impactful project, backed by a capable and committed team.
How can I pitch my company to TechWald?
Please submit your project via our online form. Be as clear and detailed as possible to help us understand the uniqueness of your company. Feel free to attach non-confidential materials to support your application.
How long does it take to receive a response?
If we are interested, we typically arrange an initial call. After receiving non-confidential materials, we evaluate the project internally—usually during our weekly investment committee—and get back to you within 2 to 3 weeks.* *Timelines may vary depending on our current workload.
Do you invest only in certain geographies?
We do not limit ourselves to specific regions, but favor companies located near our operational bases (mainly Europe and Israel) for closer collaboration.
If I contacted TechWald in the past, can I reach out again?
Absolutely. If your company has undergone significant progress since our last interaction, we’d be happy to re-evaluate. We recommend waiting at least 6 months unless major developments have occurred.
Do you require a lead role in funding rounds?
We typically prefer to lead rounds but are open to co-investing or taking a supporting role when strategically appropriate.
What support do you provide beyond capital (e.g., strategic, regulatory, commercial)?
As a team of MedTech experts, we go beyond funding. We provide hands-on support across clinical development, regulatory pathways, and commercialization. We also leverage our industry network to facilitate partnerships, recruit key talent, and accelerate go-to-market strategies—helping founders succeed from early development to market entry.
Do you sign NDAs before reviewing a project?
We do not have a proper strategy about NDAs. We tend to sign NDAs only when the interest is very high and we want to check clinical datas.
What are the most common reasons you pass on an investment?
Rejection can happen for various reasons. Sometimes the project falls outside our strategic scope or MedTech focus. In other cases, the company may be too early or too late-stage for our investment profile. We may also pass if the geographic distance limits our ability to provide hands-on support, or if we believe the founding team lacks the structure or experience needed to execute the company’s vision effectively. Every case is evaluated carefully and respectfully.
Do you support follow-on investments?
Absolutely yes.
MedTech Focus
What qualifies as a MedTech innovation in your scope?
We define MedTech encompassing medical devices and enabling technologies that improve patient care and clinical workflows. We tend to prefer implantable not invest in diagnostic and digital health.
Do you invest in pharma, biotech etc?
No, TechWald do not invest in pharma, biotech or any related field.
How do you evaluate regulatory risk?
We assess regulatory pathways, clinical strategy, and compliance from the early stages, with a focus on feasibility, expected timelines, and alignment with reimbursement and commercialization objectives.
Partnerships & Collaborations
Are you open to co-investments or syndication?
Absolutely. We have co-invested with other funds and investors in the past and are always open to strong partnerships.
Do you collaborate with hospitals, universities, or research centers?
Yes. We actively seek collaborations with academic institutions and clinical centers to support technology validation and early adoption.
General & Operational
Where is TechWald based?
Our headquarters are in Milan, Italy, with an additional office in Tel Aviv, Israel.
Who are the team members?
To learn more about our team, please visit the [Team page] on our website. We are proud to bring together deep industry knowledge and a shared passion for innovation.